Jasper Therapeutics Inc
Change company Symbol lookup
Select an option...
JSPR Jasper Therapeutics Inc
PGWFF PGG Wrightson Ltd
CRNX Crinetics Pharmaceuticals Inc
NDAQ Nasdaq Inc
PML PIMCO Municipal Income Fund II
BBLN Babylon Holdings Ltd
NEPT Neptune Wellness Solutions Inc
AEO American Eagle Outfitters Inc
BNS Bank of Nova Scotia
BAC Bank of America Corp
Go

Company profile

Jasper Therapeutics, Inc., formerly Amplitude Healthcare Acquisition Corporation, is a biotechnology company focused on hematopoietic cell transplant therapies. The Company has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The Company also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.

Closing Price
$8.48
Day's Change
0.48 (6.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.55
Day's Low
7.87
Volume
(Heavy Day)
Volume:
379,772

10-day average volume:
303,629
379,772

Jasper Therapeutics' stock more than doubles after Oppenheimer analyst's bullish call

10:12 am ET October 13, 2021 (MarketWatch)
Print

Shares of Jasper Therapeutics Inc. (JSPR) soared 106.2% in volatile morning trading, enough to pace the Nasdaq's gainers, after Oppenheimer analyst Jay Olson's bullish endorsement the day after the stock closed at a record low. The stock had been halted for volatility twice in the first half hour after the open, as trading volume swelled to 20.7 million shares. The company started trading as a biotechnology company with its "JSPR" ticker after the closing of the acquisition by special purpose acquisition company (SPAC) Amplitude Healthcare Acquisition Corp. was announced after the Sept. 24 close. From that day through Tuesday, the stock had plunged 52.3%, while the S&P 500 slipped 2.4% over the same time. Oppenheimer's Olson initiated Jasper with an outperform rating and stock price target of $21, implying a further 41% gain from current levels. "We view [Jasper] as an emerging leader in the development of novel targeted conditioning agents for hematopoietic stem cell transplantation (HSCT) with lead candidate JSP191 and proprietary engineered hematopoietic stem cell (eHSC) platform," Olson wrote in a note to clients.

-Tomi Kilgore

	

(END) Dow Jones Newswires

October 13, 2021 10:12 ET (14:12 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.